Repligen | RGEN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agilent USD 1.43B 2M 2026-06
Align Technology USD 864.87M 2.84M 2026-06
Bio Techne USD 235.92M 5.5M 2026-03
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Bruker USD 768.9M 44.3M 2026-06
Charles River Laboratories USD 2.84B 1.96B 2026-06
Danaher USD 52.58B 368M 2026-06
Dentsply International USD 1.35B 33M 2026-06
General Electric Aerospace USD 17.64B 417M 2026-06
Henry Schein USD 3.26B 84M 2026-06
Illumina USD 899M 47M 2026-06
IQVIA Holdings USD 1.77B 4.45B 2026-06
Mettler Toledo International USD 739.77M 26.57M 2026-06
Myriad Genetics USD 212.8M 16.2M 2025-12
OraSure Technologies USD 40.35M 2.45M 2025-12
Pacific Biosciences Of California USD 97.83M 41.29M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Repligen USD 183M 8.72M 2026-06
Revvity USD 603.55M 24.8M 2026-06
Standard Biotools USD 30.56M 15.16M 2026-03
Thermo Fisher Scientific USD 9.81B 716M 2026-06
Waters USD 527M 592M 2026-06
West Pharmaceutical Services USD 2.99B 200K 2026-06